0000000000281984

AUTHOR

Orhan Aktas

showing 9 related works from this author

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.

2013

Multiple sclerosis (MS) is a genetically complex disease that shares a substantial proportion of risk loci with other autoimmune diseases.1 Along these lines, ANKRD55 , originally implicated in rheumatoid arthritis, was recently reported as a potential novel MS risk gene (rs6859219, p=1.9×10−7).2 Here, we comprehensively validated this effect in independent datasets comprising 8846 newly genotyped subjects from Germany and France as well as 5003 subjects from two genome-wide association studies (GWAS). Upon meta-analysis of all available data (19 686 subjects), ANKRD55 rs6859219 now shows compelling evidence for association with MS at genome-wide significance (OR=1.19, p=3.1×10−11). Our stu…

RFXANKAdultMalemedicine.medical_specialtyMultiple SclerosisLocus (genetics)Genome-wide association studySingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideWhite PeopleMolecular geneticsDatabases GeneticGeneticsmedicineHumansGenetic Predisposition to DiseaseGenetics (clinical)Genetic associationGeneticsMultiple sclerosisMiddle Agedmedicine.diseaseAnkyrin RepeatCase-Control StudiesAnkyrin repeatFemaleCarrier ProteinsGenome-Wide Association StudyJournal of medical genetics
researchProduct

Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1

2012

Background Single nucleotide polymorphisms (SNPs) rs429358 (e4) and rs7412 (e2), both invoking changes in the amino-acid sequence of the apolipoprotein E (APOE) gene, have previously been tested for association with multiple sclerosis (MS) risk. However, none of these studies was sufficiently powered to detect modest effect sizes at acceptable type-I error rates. As both SNPs are only imperfectly captured on commonly used microarray genotyping platforms, their evaluation in the context of genome-wide association studies has been hindered until recently. Methods We genotyped 12 740 subjects hitherto not studied for their APOE status, imputed raw genotype data from 8739 subjects from five ind…

GeneticsApolipoprotein E0303 health sciencesCandidate genebusiness.industrySingle-nucleotide polymorphismContext (language use)03 medical and health sciences0302 clinical medicineMeta-analysisImmunologyGenotypeGeneticsMedicinebusinessGenotyping030217 neurology & neurosurgeryGenetics (clinical)030304 developmental biologyGenetic associationJournal of Medical Genetics
researchProduct

Genome-wide significant association with seven novel multiple sclerosis risk loci

2015

Objective A recent large-scale study in multiple sclerosis (MS) using the ImmunoChip platform reported on 11 loci that showed suggestive genetic association with MS. Additional data in sufficiently sized and independent data sets are needed to assess whether these loci represent genuine MS risk factors. Methods The lead SNPs of all 11 loci were genotyped in 10 796 MS cases and 10 793 controls from Germany, Spain, France, the Netherlands, Austria and Russia, that were independent from the previously reported cohorts. Association analyses were performed using logistic regression based on an additive model. Summary effect size estimates were calculated using fixed-effect meta-analysis. Results…

GeneticsMultiple SclerosisMultiple sclerosisCase-control studySingle-nucleotide polymorphismLocus (genetics)Genome-wide association studyBiologymedicine.diseaseLogistic regressionPolymorphism Single NucleotideGene FrequencyGenetic LociRisk FactorsCase-Control StudiesGeneticsmedicineHumansGenetic Predisposition to DiseaseAllele frequencyGenetics (clinical)Genome-Wide Association StudyGenetic association
researchProduct

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multipl…

2020

The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3). Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in the full dataset (p = 3.17 &times

Signal peptideGene isoformSignal peptidePopulationSingle-nucleotide polymorphismLocus (genetics)610 Medicine & healthBiologymultiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineSNPIL-22 binding protein isoformsignal peptideddc:610Alleleeducation610 Medicine &amp; healthlcsh:QH301-705.5Peptide sequence030304 developmental biology0303 health scienceseducation.field_of_studyautoimmuneGeneral MedicineMolecular biologylcsh:Biology (General)<i>IL22RA2</i>IL22RA2Mutation[SDV.IMM]Life Sciences [q-bio]/Immunologymutation030217 neurology & neurosurgeryAutoimmune
researchProduct

Subtle retinal pathology in amyotrophic lateral sclerosis

2014

Amyotrophic lateral sclerosis (ALS) is characterized by neuro-ophthalmological abnormalities beyond disturbed oculomotor control such as decreased visual acuity and disturbed visual evoked potentials. Here we report retinal alterations in a cohort of 24 patients with clinically definite (n = 20) or probable (n = 4) ALS as compared to matched controls. High-resolution spectral domain optical coherence tomography with retinal segmentation revealed a subtle reduction in the macular thickness and the retinal nerve fiber layer (RNFL) as well as a marked thinning of the inner nuclear layer (INL). Our data indicate an unprecedented retinal damage pattern and suggest neurodegeneration beyond the mo…

Pathologymedicine.medical_specialtymedicine.diagnostic_testgenetic structuresbusiness.industryGeneral NeuroscienceNeurodegenerationNerve fiber layerRetinalmedicine.diseaseeye diseaseschemistry.chemical_compoundmedicine.anatomical_structurechemistryOptical coherence tomographyMotor systemDecreased Visual AcuityInner nuclear layermedicineNeurology (clinical)sense organsAmyotrophic lateral sclerosisbusinessBrief CommunicationsAnnals of Clinical and Translational Neurology
researchProduct

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

2021

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particular…

Position statementmedicine.medical_specialtytreatment recommendationMedizin610 Medicine & healthReviewDiseasemultiple sclerosis03 medical and health sciences0302 clinical medicineWhite paperNeuronal damagemedicine030212 general & internal medicineRC346-429610 Medicine &amp; healthIntensive care medicinePharmacologybusiness.industryMultiple sclerosisDisease mechanismsGuidelinemedicine.diseasedisease-modifying therapy3. Good healthGroup treatmentNeurologyNeurology. Diseases of the nervous systemNeurology (clinical)businessguideline030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

2016

Multiple sclerosis (MS) is a prevalent neurological disease of complex etiology. Here, we describe the characterization of a multi-incident MS family that nominated a rare missense variant (p.G420D) in plasminogen (PLG) as a putative genetic risk factor for MS. Genotyping of PLG p.G420D (rs139071351) in 2160 MS patients, and 886 controls from Canada, identified 10 additional probands, two sporadic patients and one control with the variant. Segregation in families harboring the rs139071351 variant, identified p.G420D in 26 out of 30 family members diagnosed with MS, 14 unaffected parents, and 12 out of 30 family members not diagnosed with disease. Despite considerably reduced penetrance, lin…

0301 basic medicineProbandMaleGene ExpressionQH426-470multiple sclerosis0302 clinical medicineRisk FactorsGenotypeMissense mutationExomegeneticsguidelinesGenetics (clinical)degradationriskGeneticsLinkagedeficiencyMiddle AgedPenetrance3. Good healthPedigreeplasminogenChromosomes Human Pair 6FemalelinkageAdultGenotype610 Medicine & healthInvestigationsBiologysystemPolymorphism Single Nucleotideblood-brain-barrieractivatorMultiple sclerosisAssociation03 medical and health scienceslamininGenetic linkagemedicineGeneticsHumansAmino Acid Sequenceddc:610Molecular BiologyGenotypingAgeddiseaseSequence Homology Amino AcidMultiple sclerosisCase-control studyassociationPlasminogenmedicine.diseasediagnostic-criteria030104 developmental biologyCase-Control StudiesImmunologySequence Alignment030217 neurology & neurosurgery
researchProduct

BAX inhibitor-1 is a Ca(2+) channel critically important for immune cell function and survival.

2015

The endoplasmic reticulum (ER) serves as the major intracellular Ca(2+) store and has a role in the synthesis and folding of proteins. BAX (BCL2-associated X protein) inhibitor-1 (BI-1) is a Ca(2+) leak channel also implicated in the response against protein misfolding, thereby connecting the Ca(2+) store and protein-folding functions of the ER. We found that BI-1-deficient mice suffer from leukopenia and erythrocytosis, have an increased number of splenic marginal zone B cells and higher abundance and nuclear translocation of NF-κB (nuclear factor-κ light-chain enhancer of activated B cells) proteins, correlating with increased cytosolic and ER Ca(2+) levels. When put into culture, purifie…

0301 basic medicineProgrammed cell deathCytoplasmEncephalomyelitis Autoimmune ExperimentalCell SurvivalT-LymphocytesActive Transport Cell NucleusApoptosisBiologyEndoplasmic Reticulum03 medical and health sciencesAnimalsCalcium SignalingObesityMolecular BiologyCalcium signalingMice KnockoutOriginal PaperB-LymphocytesBAX inhibitor 1Endoplasmic reticulumNF-kappa BMembrane ProteinsCell BiologyLeukopeniaNFKB1Acquired immune systemCell biologyEnzyme ActivationMice Inbred C57BLCytosol030104 developmental biologyApoptosisCaspasesCalciumFemaleSpleen
researchProduct